Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis

Mugheddu, Cristina; Atzori, Laura; Lappi, Astrid; Pau, Monica; Murgia, Severino; Rongioletti, Franco

doi:10.1111/jdv.14234

Cited by 37 publications

(26 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its efficacy and safety for GPP patients have been reported in a recent open‐label trial . Several case studies of GPP successfully treated with secukinumab have also been reported . In 2016, another anti‐IL‐17 antibody, ixekizumab, and an anti‐IL‐17 receptor antibody, brodalumab, were approved for health insurance coverage in Japan for patients with psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.…”

Section: Chapter V: Strength Of Recommendations and Comments For Eachmentioning

confidence: 99%

“…142 Several case studies of GPP successfully treated with secukinumab have also been reported. [143][144][145] In 2016, another anti-IL-17 antibody, ixekizumab, and an anti-IL-17 receptor antibody, brodalumab, were approved for health insurance coverage in Japan for patients with psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. The efficacy and safety of ixekizumab and brodalumab including GPP patients in an open-label trial have been reported.…”

Section: Cq16 Are Biologics Other Than Tnf-a Inhibitors Effective Fomentioning

confidence: 99%

See 1 more Smart Citation

Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP

Fujita

Terada

Hayama

et al. 2018

The Journal of Dermatology

198

456

View full text Add to dashboard Cite

Generalized pustular psoriasis (GPP) is a rare disease characterized by recurrent fever and systemic flushing accompanied by extensive sterile pustules. The committee of the guidelines was founded as a collaborative project between the Japanese Dermatological Association and the Study Group for Rare Intractable Skin Diseases under the Ministry of Health, Labour, and Welfare Research Project on Overcoming Intractable Diseases. The aim of the guidelines was to provide current information to aid in the treatment of patients with GPP in Japan. Its contents include the diagnostic and severity classification criteria for GPP, its pathogenesis, and recommendations for the treatment of GPP. Since there are few clinical trial data with high levels of evidence for this rare disease, recommendations by the committee are described in the present guidelines.

show abstract

Section: Chapter V: Strength Of Recommendations and Comments For Eachmentioning

confidence: 99%

Section: Cq16 Are Biologics Other Than Tnf-a Inhibitors Effective Fomentioning

confidence: 99%

Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP

Fujita

Terada

Hayama

et al. 2018

The Journal of Dermatology

198

456

View full text Add to dashboard Cite

show abstract

“…Some success was found with the use of anakinra, an IL‐1Ra . Good efficacy has been reported with the use of secukinumab and ixekizumab, which are anti‐IL‐17A monoclonal antibodies . A promising new treatment option with a rapid onset of action is brodalumab, an anti‐IL‐17‐receptor A monoclonal antibody .…”

Section: Treatmentmentioning

confidence: 99%

Generalized pustular psoriasis: a review and update on treatment

Hoegler

John

Handler

et al. 2018

Acad Dermatol Venereol

160

193

View full text Add to dashboard Cite

Generalized pustular psoriasis (GPP) is a subtype of pustular psoriasis characterized by painful and occasionally disfiguring cutaneous manifestations with sepsis-like systemic symptoms. Affecting any age and race, GPP can occur with other forms of psoriasis or by itself. Stimuli for flares include medications, infections and environmental triggers. The interleukin family and caspase recruitment domain family have been implicated in its pathogenesis. Other forms of pustular psoriasis include impetigo herpetiformis, palmoplantar pustular psoriasis, annular pustular psoriasis and acrodermatitis continua of Hallopeau. Treatment is not well established, but includes the use of retinoids, methotrexate, cyclosporine, corticosteroids, TNF-alpha inhibitors, topical therapy and phototherapy. The use of TNF-alpha inhibitors may result in the formation of antidrug antibodies and should be administered with methotrexate.

show abstract

“…Since 2015 it has been approved by the Food and Drug Administration in the U.S.A. and it has gained increasing popularity for the treatment of plaque psoriasis. However, there are very few reports showing secukinumab as an option for treating EP …”

Section: Summary Of the 10 Cases Of Erythrodermic Psoriasismentioning

confidence: 99%

Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series

2018

View full text Add to dashboard Cite

Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis

Cited by 37 publications

References 10 publications

Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP

Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP

Generalized pustular psoriasis: a review and update on treatment

Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series

Contact Info

Product

Resources

About